Blood test clues could sharpen cervical cancer treatment
NCT ID NCT05673252
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if these markers could help doctors better classify risk and choose the most appropriate treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venous blood sample and biopsy
- What this could lead to
- If inflammatory markers predict risk, doctors could better tailor treatment for cervical cancer patients.
- What could go wrong
- This is an observational study, so it can't prove cause and effect. Results may not change practice without further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Università degli Studi della Campania Luigi Vanvitelli
Naples, Naples, 80138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?